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14 Oral Presentationsa concern is that T cells bearing immunogenic transgenes, such as
those coding for mouse proteins, bacterial selection genes, or viral
suicide genes, would be targeted by the recipient’s immune system
and deleted. We report now that we have reduced the risk of clear-
ance of adoptively transferred genetically modified T cells due to
a host-versus-graft immune-mediated reaction directed to the xeno-
genic components of the CAR and its vector. To decrease immuno-
genicity, we generated a CD19-specific CAR encoded by all-human
transgenes (designated hCAR), wherein the murine CD19-specific
scFv is replaced with a human scFv of a CD19-specific mAb, derived
from mice immunized with CD19 and expressing human immuno-
globulin genes. Primary human T cells were electro-transferred
with the hCAR transgene, using Sleeping Beauty (SB) transposition,
and co-cultured with artificial antigen presenting cells expressing
CD19 antigen and co-stimulatory molecules, resulting in expansion
and stable expression of hCAR without the need for concomitant
drug selection. The hCAR1 T cells could be detected by flow cy-
tometry and Western blot analysis and demonstrated specific lysis
of CD191 tumor targets. This report demonstrates technology
for generating CD19-specific hCAR1 T cells while avoiding ex-
pression of immunogenic proteins (e.g. murine scFv) and will likely
be of interest to the many investigators considering CAR1 T cells
for treatment of tumors.31
COMPREHENSIVE TYPING OF 1143 SINGLE NUCLEOTIDE POLYMOR-
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A wide range of genetic polymorphisms has been studied in the
context of hematopoietic stem cell transplantation. To date, most
of these analyses have assessed a limited number of arbitrarily cho-
sen SNPs in a single or limited number of genes. We created an Af-
fymetrix custom SNP array and evaluated a total of 1143 SNPs in
220 distinct immune effector genes in 187 hematopoietic stem
cell transplant (HSCT) recipients and their sibling donors. Where
possible, SNPs that have been previously evaluated in the context
of GVHD (e.g. IL-10 SNPs) were included on the array. Genomic
DNA was extracted from peripheral blood mononuclear cells
(PBMC) obtained from patients and their sibling donors. All pa-
tients were in remission at the time of sampling, all had undergone
HSCT at the Dana-Farber Cancer Institute between 1998 and 2005
and all samples were drawn prior to transplantation. The trans-
plants included myeloablative and non-myeloablative conditioning
regimens, T cell depleted (TCD) and non-TCD grafts and sex
matched and sex mis-matched donors. Using dChip software, we
evaluated each of the SNPs on the array in patients and in their do-
nors for an association between genotype and the development of
acute GVHD. Univariate and multivariate statistical analyses were
performed using the Cochran-Mantel-Haenzel test and a logistic
regression model adjusting for age, sex mismatch and other trans-
plant characteristics. The SNPs rs1063340 and rs1634508, that
are believed to regulate the function of CCL3 and CCL4 respec-
tively, were most highly associated with protection against aGVHD
(p\ 0.003), demonstrating an odds ratio (OR) of 0.6 for risk of
acute GVHD in the logistic regression analysis. The SNP
rs11575584, which is thought to regulate CCL27 was most highly
associated with risk of aGVHD (p 5 0.005), with an OR of 2 in
the same logistic regression model. CCL3 and CCL4 are chemo-
kine ligands for CCR5 while CCL27 is a skin-associated chemo-
kine, which interacts with the CCR10 receptor. The CCR5
deletion mutation (which protects against HIV infection) has re-
cently been associated with a reduced risk of aGVHD and increased
epidermal expression of CCL27 has been shown in patients with cu-
taneous aGVHD. This study is the most comprehensive evaluation
to date of functional genetic polymorphisms on the risk of aGVHD.
It suggests that the CCL3-CCL4-CCR5 and CCL27-CCR10 path-
ways play important roles in the pathogenesis of aGVHD and fur-
ther investigation of these pathways is warranted.32
ROLE OF STAT3 SIGNALING IN GVHD AND GVL
Radojcic, V., Pletneva, M.A., Yen, H.-R., Pardoll, D.M., Drake, C.G.,
Luznik, L. Johns Hopkins University.
Growing evidence suggests that STAT3 signaling in CD41 T-
cells plays a key role in the pathogenesis of autoimmunity. We
tested the role of the same pathway in the induction of GVHD
and GVL response in a murine model of alloSCT. Using the
MHC-matched B10.D2/BALB/c model in which GVHD is
CD41 T-cell-mediated and has clinicopathologic features consis-
tent with human chronic sclerodermatous GVHD, we examined
the role of STAT3 signaling in CD41 T-cells in the pathogenesis
of GVHD and GVL response. After conditioning (775 cGy) recip-
ient mice received B10.D2 T-cell depleted (TCD) bone marrow
(BM) and equivalent of 12  106 splenocytes (9.3  106 TCD sple-
nocytes, repleted with 106 wild-type (WT) CD81 and 1.8  106
WT, or CD4-Cre  STAT3flox/flox (STAT3KOCD41) T-cells),
a dose shown to induce all signs of GVHD. We reproducibly in-
duced all signs of chronic GVHD in chimeras receiving WT
CD41 T-cells, but not in chimeras injected with STAT3KOCD41
T-cells (median score of 0.0 vs. 5.2; P\ .001). In situ studies showed
that cutaneous GVHD was accompanied by prominent dermal in-
filtration of donor-derived inflammatory monocytes and complete
turnover to donor CD11c1 epidermal DC chimerism in chimeras
receiving WT but not STAT3KOCD41 T-cells (P\ .001). Splenic
CD11c1DCs, CD41 and CD81T-cell chimerism was nearly com-
pletely donor-derived and did not differ between the two sets of de-
scribed chimeras. We also found that in this model, pathogenic
CD41T-cells do not acquire TH17 phenotype and that STAT3 sig-
naling disruption leads to expansion of Foxp31CD41 T-cells. To
examine the role of STAT3 pathway in eliciting GVL response,
we developed a model of preestablished disease in which 106 A20
lymphoma cells were administered to recipients 10 days prior to al-
loSCT. Addition of GVH inoculum containing STAT3KOCD41
T-cells enabled potent GVL response when compared to animals
receiving only TCD BM, or BM with added TCD SPL (P \
.001). However, it was inferior to that observed in the animals re-
ceiving WT CD41 T-cells (P\ .001). Our findings indicate that:
a) intact STAT3 signaling in CD41 T-cells is required for clinical
manifestations of GVHD in B10.D2/BALB/c model; b) commit-
ment of STAT3KOCD41 T-cells to regulatory Foxp31 lineage is
likely a result of their insensitivity to IL-6 in the abundance of
TGF-b; c) STAT3 ablation enables preservation of GVL, while re-
ducing clinical manifestations of GVHD. Further exploration of the
role of STAT3 pathway in posttransplant events is required.33
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